BLT (ASX) Ann: Interim Report 3 Months to 30 September 2017

Originally posted by Hoyland ↑

If any $ had been committed subject to conditions being met, then such an agreement would have to be reported to the ASX. The fact that there has been no such lodgement tells me that there is no background deal that is waiting in the wings while unknown shareholders accumulate. Also, the "grant" is a R&D tax incentive and so the more we spend on R&D, the more we can claim back.

The Path to Value Creation is not new. A very similar caption was used for some presentations in the past. We all know what impact that had.

All our partners are ones where we pay them money, so how selective are we? True, our licencees do pay some revenue to us, but not much more than the cost of a pub meal and a beer.

If dilution is not on the cards, why have we got a $20M shelve registration waiting to be actioned?

I admire your optimism, but I think that the only way we will avoid dilution is if we partner on OPMD or Nant provides non-dilutive capital. I don't think any of your scenarios are plausible.

Expand

Hi Hoyland, your quote below is the creative loop hole I am surprised Nant has not capitalized on by running more of their cancer programs through Benitec.

"Also, the "grant" is a R&D tax incentive and so the more we spend on R&D, the more we can claim back." (non dilutive funding)

Why wouldn't Nant do a lot of R&D for cancer through Benitec where you would receive a tax credit & beneficial dollar exchange rate?

At the end of the day Nant's core focus is on cancer not AMD, OPMD or HBV.

I Agree we should partner OPMD with big pharma to get get more upfront non -dilutive capital and get some much needed creditability.

Jerel Banks is the chairman has a vested interest in making sure Benitec focuses on Car-t joint ventures to please his boss Patrick Soon.

Our partner Regen BioPharma, dCellVax Gene-Silenced Breast cancer immunotherapy is where we could allocate some of our opmd money to help develop dCellVax for a larger equity stake in the program.